FRESOLIMUMAB
Drug
GENZYME CORPORATION
Total Payments
$140,000
Transactions
2
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $80,000 | 1 | 0 |
| 2018 | $60,000 | 1 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $140,000 | 2 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Multicenter study to evaluate safety of fresolimumab in adults with moderate-to-severe Osteogenesis Imperfecta | GENZYME CORPORATION | $140,000 | 0 |
Top Doctors Receiving Payments for FRESOLIMUMAB
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Houston, TX | $140,000 | 2 |
Ad
Manufacturing Companies
- GENZYME CORPORATION $140,000
Product Information
- Type Drug
- Total Payments $140,000
- Total Doctors 0
- Transactions 2
About FRESOLIMUMAB
FRESOLIMUMAB is a drug associated with $140,000 in payments to 0 healthcare providers, recorded across 2 transactions in the CMS Open Payments database. The primary manufacturer is GENZYME CORPORATION.
Payment data is available from 2018 to 2019. In 2019, $80,000 was paid across 1 transactions to 0 doctors.
The most common payment nature for FRESOLIMUMAB is "Unspecified" ($140,000, 100.0% of total).
FRESOLIMUMAB is associated with 1 research study, including "Multicenter study to evaluate safety of fresolimumab in adults with moderate-to-severe Osteogenesis Imperfecta" ($140,000).